Glympse Bio raises more than $46M in Series B round for biosensor technology July 15, 2020 Auto Bot ARCH Venture Partners, biopharma nl, Cambridge Massachusetts, Diagnostics, Gilead Sciences, NASH, nonalcoholic steatohepatitis, Startups 0 The company is developing biosensors, initially for NASH, that could be used in place of liver biopsy and have applicability in development of drugs for the disease.